Form 4: LifeCore Biomedical CEO Paul Josephs Disposes of Shares to Cover Tax Obligations

Paul Josephs, CEO of LifeCore Biomedical, disposed of 21,532 shares of common stock on May 20, 2025, to satisfy tax withholding obligations related to RSU vesting.

Summary

• On May 20, 2025, Paul Josephs, the CEO of LifeCore Biomedical, disposed of 21,532 shares of common stock.
• The transaction was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The shares were disposed of at a price of $6.63 per share.
• Following the transaction, Josephs directly owns 538,185 shares of LifeCore Biomedical.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission (SEC).

Sentiment

Score: 6

Explanation: The document is neutral. It simply reports a transaction related to tax obligations, which is a common occurrence. There is no indication of positive or negative sentiment towards the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Disposals to cover tax obligations are common and don't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The disposal of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the transaction.

Key Dates

Keywords

LifeCore Biomedical, Paul Josephs, Form 4, SEC, Share Disposal, RSU Vesting, Tax Obligations, LFCR, Director, Chief Executive Officer